Details for New Drug Application (NDA): 219592
✉ Email this page to a colleague
The generic ingredient in GOZELLIX is gallium ga-68 gozetotide. There are sixteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the gallium ga-68 gozetotide profile page.
Summary for 219592
| Tradename: | GOZELLIX |
| Applicant: | Telix Innovations |
| Ingredient: | gallium ga-68 gozetotide |
| Patents: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 219592
Generic Entry Date for 219592*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 219592
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| GOZELLIX | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 219592 | NDA | Telix Innovations SA | 84552-500 | 84552-500-25 | 1 KIT in 1 CARTON (84552-500-25) * 2.5 mL in 1 VIAL, MULTI-DOSE (84552-502-25) * 6.4 mL in 1 VIAL, MULTI-DOSE (84552-503-64) * 2 mL in 1 AMPULE (84552-504-25) * 1 POWDER, FOR SOLUTION in 1 VIAL, MULTI-DOSE (84552-501-25) |
| GOZELLIX | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 219592 | NDA | Telix Innovations SA | 84552-500 | 84552-500-64 | 1 KIT in 1 CARTON (84552-500-64) * 2.5 mL in 1 VIAL, MULTI-DOSE (84552-502-25) * 6.4 mL in 1 VIAL, MULTI-DOSE (84552-503-64) * 2 mL in 1 AMPULE (84552-504-25) * 1 POWDER, FOR SOLUTION in 1 VIAL, MULTI-DOSE (84552-501-25) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | N/A | ||||
| Approval Date: | Mar 20, 2025 | TE: | RLD: | Yes | |||||
| Patent: | 11,027,031 | Patent Expiration: | Jul 28, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER | ||||||||
Complete Access Available with Subscription
